UNSPSC 51401538: Midazolam

This classification denotes a benzodiazepine with the molecular formula C18H13ClFN3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R60L0SM5BC, chemically known as 8-chloro-6-(o-fluorophenyl)-1-methyl-4h-imidazo(1,5-a)(1,4)benzodiazepine but generally known as midazolam, which bears US NIH Compound Identifier 4192. European Medicines Agency schedules Midazolam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08950MIG.

UNSPSC 51401538 Midazolam, a Commodity code, encompasses pharmaceutical procurement by state and local health agencies, though recent opportunities tagged under this code show limited direct midazolam solicitation and instead reflect broader pharmaceutical supply and emergency-response drug purchasing. State and local buyers under this code include county health departments, state health and human services commissions, and cooperative purchasing alliances serving multi-jurisdictional networks. The work involves securing supply agreements for generic pharmaceuticals and emergency medications, with vendors expected to manage distribution through authorized wholesalers, maintain FDA compliance and Good Manufacturing Practices certification, carry comprehensive insurance including commercial general liability coverage, and meet strict product availability and shelf-life standards. Recent opportunities demonstrate that procurement ranges from emergency-response drugs (naloxone and drug deactivation systems) to broader generic pharmaceutical catalogs with multiple SKUs, NDCs, and dosage configurations.

Procurement activity under the code spans Florida, Texas, and Minnesota-Oregon through the MMCAP cooperative purchasing vehicle. Representative recent opportunities include Seminole County, Florida's IFB60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 annual units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to the county community health building; the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription fulfillment capabilities outside traditional pharmacy benefit manager arrangements; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers with product availability required by May 15, 2026. The MMCAP procurement emphasizes price competitiveness (75 percent evaluation weight), compliance with DSCSA chain-of-custody requirements, and performance penalties for late reporting or missed onboarding. No explicit set-aside designations appear across these solicitations.